Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.

Conclusions: Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki-67 may play a role as predictive factor for response to neoadjuvant chemotherapy.
PMID: 32069523 [PubMed - as supplied by publisher]

Source: The Korean Journal of Internal Medicine - February 20, 2020 Category: Internal Medicine Authors: Won HS, Kim YS, Kim JS, Chang ED, Na SJ, Whang IY, Lee DS Tags: Korean J Intern Med Source Type: research